Isaura Santos,  —

Bianca Nicholas made history when she and Alex Larke, together known as Electro Velvet, represented the United Kingdom at the Eurovision Song Contest 2015 with the song “Still in Love with You.” Bianca suffers from cystic fibrosis, and the Cystic Fibrosis Trust is raising awareness through her participation in the…

DiscoveryBioMed, Inc. (DMB) has discovered and is currently developing a new class of small molecule monotherapy that utilizes the pathophysiological features of cystic fibrosis and works on two drug targets. In Cystic Fibrosis, patients’ production of the CFTR protein and ENaC ion channel is abnormal, leading to a dysfunctional CFTR activity and over-activity of ENaC.

AbbVie recently announced that the 2015 AbbVie CF Scholarship is now open and accepting applications from both graduate and undergraduate students. This scholarship supports and honors young adults suffering with cystic fibrosis (CF) in their pursuit of higher education. Students can apply for the scholarship until May 27, 2015, 10 a.m. (central…

Anthera Pharmaceuticals recently announced that it received a $3 million award from the Cystic Fibrosis Foundation Therapeutics to support both the manufacturing and clinical development of Sollpura™ (liprotamase), Anthera’s new pancreatic enzyme replacement therapy. Cystic Fibrosis Foundation Therapeutics is an affiliate of the Cystic Fibrosis Foundation, a non-profit organization. Anthera Pharmaceuticals is a…

Vertex Pharmaceuticals Incorporated recently received approval from the United States Food and Drug Administration for Kalydeco® (ivacaftor) to treat children aged between 2 and 5 who suffer with cystic fibrosis (CF) and carry specific mutations in the CFTR gene. Children who carry one of ten different mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, including G551D,…

Research and Markets recently released their “Cystic Fibrosis Market in Europe 2015-2019“ report, which offers an overview of current activities involving pipeline therapeutics in the ongoing fight against cystic fibrosis. Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. Its primary symptoms include breathing difficulties, elevated…

Concert Pharmaceuticals Inc. recently announced that their Phase 1 clinical program for deuterium-modified ivacaftor, a potentially disease-modifying treatment to address cystic fibrosis, has been initiated. Ivacaftor is available under the name Kalydeco®. This Phase 1 trial will be a crossover assessment to compare two different proprietary deuterium-modified compounds with the goal of…

N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm committed to developing product candidates to address cystic fibrosis (CF), recently announced that the company has changed its name to Nivalis Therapeutics, Inc. Nivalis Therapeutics’ lead product candidate is N91115, a new inhibitor of S-nitrosoglutathione reductase (GSNOR) for the treatment of CF. The company’s new name, Nivalis…

The Mauli Ola Foundation’s (MOF) 2014 national Ohana Tour will finish on the North Shore of Oahu, and the event will include pediatric visits and Surf Experience Days to help those suffering with cystic fibrosis. Jamie O’Brien, the pipeline master, will be hosting the final 2014 Surf Experience which…

Cempra, Inc received clearance to initiate Phase 1b and Phase 2 / 3 studies that will test their solithromycin antibiotic in newborn to 17 year-old patients. The experimental antibiotic could eventually offer new therapeutic options to cystic fibrosis patients in fighting bacterial lung infections. Intravenous, oral suspension formulas, and…